Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 15Active not recruiting 5Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Multiple Myeloma 25Leukemia, Myeloid, Acute 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Lymphoma 21Burkitt Lymphoma 19Myelodysplastic Syndromes 17Leukemia 17Lymphoma, Non-Hodgkin 15Lymphoma, Follicular 15Lymphoma, Large B-Cell, Diffuse 14Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Mantle-Cell 12Lymphoma, B-Cell, Marginal Zone 12Neoplasms, Plasma Cell 11Lymphoma, Large-Cell, Immunoblastic 11Hodgkin Disease 11Breast Neoplasms 11Recurrence 10Congenital Abnormalities 9Sarcoma 8Dendritic Cell Sarcoma, Interdigitating 8Myeloproliferative Disorders 7Leukemia, Myelomonocytic, Juvenile 7Leukemia, Myeloid, Chronic-Phase 7Lymphoma, T-Cell, Cutaneous 6Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 6Leukemia, Myeloid, Accelerated Phase 6Leukemia, Hairy Cell 6Central Nervous System Neoplasms 6Sezary Syndrome 5

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Filgrastim × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡